Bacterial infections of the stomach are rare as the harsh acidic environment constitutes a protective barrier. Therefore, infections are commonly associated with prior weakening of the protective measures for example by gastroduodenal surgery, or immunocompromised states. C. perfringens exploits these predisposing circumstances and possesses a very high virulence due to its fast growth. An infection with this Gram-positive, anaerobic, and gas-forming bacterium can manifest itself in emphysematous gastritis or the wound infection gas gangrene, amongst other pathophysiological conditions. While the incidence rate is relatively low, both diseases are associated with high lethality. Treatment options involve antibiotic therapy and surgical intervention. The development of new therapies for C. perfringens infections is crucial given the development of resistances by C. perfringens against currently used antibiotics (clindamycin, penicillin, metronidazole, etc.), and the prevalence of penicillin allergies. With the promising in vitro activity of Fdx, the synthesis of acid-stable glycomimetics constitutes a viable strategy to extend the portfolio of treatment options against